GlassScriptPhysician profile
Tyler Kaplan
NPI 1861887358
$548,992.82
in general payments reported to CMS, 2019-2025
15 companies · $143K in 2025
The $143K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $2,004 · 2021: $2,601 · 2022: $74K · 2023: $155K · 2024: $172K · 2025: $143K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $337K · Travel and Lodging: $56K · Consulting Fee: $51K · Honoraria: $16K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $337,218.00 |
| Travel and Lodging | $55,954.10 |
| Consulting Fee | $50,670.38 |
| Honoraria | $15,775.00 |
| Food and Beverage | $10,641.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $271,764.84 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $119,065.04 | 2021-2025 | Vumerity, Tysabri, Tysabri |
| Tg Therapeutics, INC. | $60,133.98 | 2022-2025 | Briumvi |
| Amgen INC. | $54,898.13 | 2024-2025 | Uplizna |
| Horizon Therapeutics Plc | $22,490.18 | 2022-2023 | Uplizna |
| Genentech USA, INC. | $9,019.95 | 2020-2023 | Ocrevus |
| Genzyme Corporation | $7,592.21 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $2,481.36 | 2021-2022 | |
| Celgene Corporation | $608.03 | 2020-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $515.48 | 2019-2024 | |
| Allergan, INC. | $145.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $121.91 | 2024 | Ultomiris |
| Ani Pharmaceuticals, INC. | $74.72 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $48.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.93 | 2023 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.